Crescita Therapeutics Inc.
CRRTF
$0.31
-$0.04-10.71%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.92M | 4.51M | 2.46M | 4.93M | 2.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.92M | 4.51M | 2.46M | 4.93M | 2.64M |
| Cost of Revenue | 1.84M | 1.74M | 1.25M | 2.79M | 1.19M |
| Gross Profit | 2.07M | 2.76M | 1.22M | 2.14M | 1.44M |
| SG&A Expenses | 1.81M | 1.99M | 1.62M | 1.87M | 1.96M |
| Depreciation & Amortization | 278.80K | 255.10K | 246.00K | 260.70K | 228.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.03M | 4.08M | 3.20M | 5.03M | 3.49M |
| Operating Income | -117.60K | 421.40K | -740.00K | -100.70K | -859.30K |
| Income Before Tax | 546.70K | 576.80K | -649.40K | -125.70K | -759.60K |
| Income Tax Expenses | -- | -- | -- | -10.00K | -- |
| Earnings from Continuing Operations | 546.70K | 576.80K | -649.40K | -115.70K | -759.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 546.70K | 576.80K | -649.40K | -115.70K | -759.60K |
| EBIT | -117.60K | 421.40K | -740.00K | -100.70K | -859.30K |
| EBITDA | 161.20K | 676.50K | -494.00K | 67.50K | -630.50K |
| EPS Basic | 0.03 | 0.03 | -0.03 | -0.01 | -0.04 |
| Normalized Basic EPS | 0.02 | 0.02 | -0.02 | 0.00 | -0.02 |
| EPS Diluted | 0.03 | 0.03 | -0.03 | -0.01 | -0.04 |
| Normalized Diluted EPS | 0.02 | 0.02 | -0.02 | 0.00 | -0.02 |
| Average Basic Shares Outstanding | 18.84M | 18.93M | 19.03M | 19.12M | 19.27M |
| Average Diluted Shares Outstanding | 18.85M | 19.04M | 19.03M | 19.12M | 19.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |